Search Results - "Burch, Patrick A"

Refine Results
  1. 1
  2. 2
  3. 3

    Obesity adversely affects survival in pancreatic cancer patients by McWilliams, Robert R., Matsumoto, Martha E., Burch, Patrick A., Kim, George P., Halfdanarson, Thorvardur R., de Andrade, Mariza, Reid‐Lombardo, Kaye, Bamlet, William R.

    Published in Cancer (01-11-2010)
    “…BACKGROUND: Higher body‐mass index (BMI) has been implicated as a risk factor for developing pancreatic cancer, but its effect on survival has not been…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer by Higano, Celestia S., Schellhammer, Paul F., Small, Eric J., Burch, Patrick A., Nemunaitis, John, Yuh, Lianng, Provost, Nicole, Frohlich, Mark W.

    Published in Cancer (15-08-2009)
    “…BACKGROUND: Sipuleucel‐T is an investigational active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. The…”
    Get full text
    Journal Article
  9. 9

    Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson by Chaiteerakij, Roongruedee, Petersen, Gloria M, Bamlet, William R, Chaffee, Kari G, Zhen, David B, Burch, Patrick A, Leof, Emma R, Roberts, Lewis R, Oberg, Ann L

    Published in Journal of clinical oncology (01-06-2016)
    “…The inclusion of metformin in the treatment arms of cancer clinical trials is based on improved survival that has been demonstrated in retrospective…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Predictors of survival from urachal cancer : A mayo clinic study of 49 cases by MOLINA, Julian R, FERNANDO QUEVEDO, J, FURTH, Alfred F, RICHARDSON, Ronald L, ZINCKE, Horst, BURCH, Patrick A

    Published in Cancer (01-12-2007)
    “…Outcome results of a long-term analysis of urachal cancer using a new staging system are presented. The authors analyzed clinical outcomes from 49 patients…”
    Get full text
    Journal Article
  12. 12

    Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study by Halfdanarson, Thorvardur R, Bamlet, William R, McWilliams, Robert R, Hobday, Timothy J, Burch, Patrick A, Rabe, Kari G, Petersen, Gloria M

    Published in Pancreas (01-11-2014)
    “…Pancreatic neuroendocrine tumors (PNETs) are uncommon, and little is known about their risk factors and association with other cancers. We evaluated whether…”
    Get full text
    Journal Article
  13. 13

    Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma by Johnson, Derek R., Kimmel, David W., Burch, Patrick A., Cascino, Terrence L., Giannini, Caterina, Wu, Wenting, Buckner, Jan C.

    Published in Neuro-oncology (Charlottesville, Va.) (01-05-2011)
    “…The objective of this phase II study was to evaluate the efficacy and safety of subcutaneous octreotide therapy for the treatment of recurrent meningioma and…”
    Get full text
    Journal Article
  14. 14

    A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors by Delaunoit, Thierry, Burch, Patrick A, Reid, Joel M, Camoriano, John K, Kobayash, Tomowo, Braich, Theodore A, Kaur, Judith S, Rubin, Joseph, Erlichman, Charles

    Published in Investigational new drugs (01-07-2006)
    “…CS-682 (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl)-N4-palmitoylcytosine) is a novel orally administered 2'-deoxycytidine-type antimetabolite, which…”
    Get full text
    Journal Article
  15. 15

    Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study by Hart, Phil A, Law, Ryan J, Frank, Ryan D, Bamlet, William R, Burch, Patrick A, Petersen, Gloria M, Rabe, Kari G, Chari, Suresh T

    Published in The American journal of gastroenterology (01-09-2014)
    “…Diabetes mellitus (DM) has a bidirectional association with pancreatic cancer (PaC); however, its effect on clinical outcomes has not been thoroughly…”
    Get full text
    Journal Article
  16. 16

    A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma by Jatoi, Aminah, Ellison, Neil, Burch, Patrick A., Sloan, Jeff A., Dakhil, Shaker R., Novotny, Paul, Tan, Winston, Fitch, Tom R., Rowland, Kendrith M., Young, Charles Y. F., Flynn, Patrick J.

    Published in Cancer (15-03-2003)
    “…BACKGROUND Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. This Phase II…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma by De Vreede, Ilja, Steers, Jeff L., Burch, Patrick A., Rosen, Charles B., Gunderson, Leonard L., Haddock, Michael G., Burgart, Lawrence, Gores, Gregory J.

    Published in Liver transplantation (01-05-2000)
    “…Orthotopic liver transplantation (OLT) alone for unresectable cholangiocarcinoma is often associated with early disease relapse and limited survival. Because…”
    Get full text
    Journal Article
  19. 19

    Priming Tissue-specific Cellular Immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer by Burch, P A, Breen, J K, Buckner, J C, Gastineau, D A, Kaur, J A, Laus, R L, Padley, D J, Peshwa, M V, Pitot, H C, Richardson, R L, Smits, B J, Sopapan, P, Strang, G, Valone, F H, Vuk-Pavlović, S

    Published in Clinical cancer research (01-06-2000)
    “…We attempted to induce therapeutic immunity against prostate-derived tissues in patients suffering from progressive hormone-refractory metastatic prostate…”
    Get full text
    Journal Article
  20. 20

    Topotecan in previously treated advanced urothelial carcinoma : an ECOG phase II trial by WITTE, R. S, MANOLA, J, BURCH, P. A, KUZEL, T, WEINSHEL, E. L, LOEHRER, P. J

    Published in Investigational new drugs (01-01-1998)
    “…[corrected] Chemotherapeutic agents are playing an increasing role in the management of urothelial carcinoma. Despite recent advances in the treatment of this…”
    Get full text
    Journal Article